ASKA Pharmaceutical Holdings Co.,Ltd.
Fiscal Year Ending March 2026 Q3 Financial Summary [Japanese GAAP] (Consolidated)
For the third quarter of the fiscal year ending March 2026, net sales amounted to ¥54,486 million (9.1% Year-over-Year increase), operating income was ¥4,911 million (10.6% Year-over-Year decrease), and net income attributable to owners of the parent was ¥3,904 million (4.7% Year-over-Year decrease).
Key Figures
- Net Sales: ¥54,486 million (9.1% Year-over-Year increase)
- Operating Income: ¥4,911 million (10.6% Year-over-Year decrease)
- Net Income Attributable to Owners of Parent: ¥3,904 million (4.7% Year-over-Year decrease)
AI要約
Overview of Performance
During the consolidated cumulative third quarter of the fiscal year ending March 2026, net sales reached ¥54,486 million (9.1% increase Year-over-Year), driven by steady performance in the pharmaceutical and animal health businesses as well as increased contributions from overseas operations. Conversely, operating income was ¥4,911 million (10.6% decrease Year-over-Year), ordinary income was ¥4,854 million (10.9% decrease Year-over-Year), and net income attributable to owners of the parent was ¥3,904 million (4.7% decrease Year-over-Year). The primary cause of the profit decline was increased selling, general and administrative expenses, including higher research and development costs.
Segment Performance
The pharmaceutical business recorded net sales of ¥45,332 million (2.9% increase Year-over-Year), with core products "Lelmina," "Droeth," "Thyradin," and "Rifixima" showing sales growth; however, segment profit was ¥5,822 million (6.1% decrease Year-over-Year). The animal health business achieved net sales of ¥5,759 million (1.0% increase Year-over-Year) and segment profit of ¥368 million (22.6% increase Year-over-Year). The overseas business, which newly consolidated a Vietnamese subsidiary, posted net sales of ¥3,240 million and segment profit of ¥70 million. Other businesses recorded net sales of ¥153 million (7.7% decrease Year-over-Year) and a loss of ¥28 million.
Financial Position and Outlook
Total assets amounted to ¥112,699 million (an increase of ¥8,404 million from the end of the previous fiscal year), liabilities were ¥37,956 million (increase of ¥5,475 million), and net assets stood at ¥74,743 million (increase of ¥2,928 million). The equity ratio was 61.0%, down 1.6 points from the previous fiscal year-end. There is no change to the consolidated earnings forecast for the fiscal year ending March 2026, with expected net sales of ¥71,000 million, operating income of ¥6,000 million, and net income attributable to owners of the parent of ¥5,000 million.
